ArticleDiscover oncology2025
Mapping the research landscape of nanotechnology based immunotherapy for hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global evolution of ferroptosis research: a comprehensive bibliometric analysis of publication trends, geographic patterns, pharmacological innovation, and translational progress from inception through 2025.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAdvances in nanotechnology have introduced novel methodologies for immunotherapy targeting hepatocellular carcinoma (HCC). This study aims to develop a knowledge map and identify potential research hotspots in this field through bibliometric analysis.
methodsPublications on HCC immunotherapy utilizing nanotechnology from 2005 to 2024 were obtained from the Web of Science Core Collection (WoSCC). Data visualization and statistical analysis were primarily conducted using VOSviewer, CiteSpace, R software, and Microsoft Office Excel 2021.
resultsThe systematic search initially retrieved 600 publications from WoSCC, of which 10 were excluded during screening, yielding 590 publications on nanotechnology applications in HCC immunotherapy. Notably, the annual publication count surged from 44 papers in 2020 to 159 papers in 2024, representing an impressive 261% increase over this four-year period. China emerged as the foremost country in publishing volume and international collaborations, although its articles receive relatively few average citations. The USA, ranking second in output, achieves the highest average citation count. The timeline visualization of reference reveals three distinct phases (2005–2009, 2010–2018, and 2019–2024) with the following seven reference clusters: #0 cancer chitosan nanoparticle, #1 hepatocellular carcinoma, #2 antigen presentation, #3 carbon nanotube, #4 targeting PD-L1 expression, #5 natural killer cell, and #6 liver metastases. “Cancer microenvironment”, “drug delivery”, “immunogenic cell death”, and “combination therapy” showed extremely high occurrence frequencies. “mRNA”, “mRNA delivery”, “metabolism” were the key keywords that have emerged recently.
conclusionNanotechnology-based immunotherapy field has evolved from foundational nanoparticle development (2005–2009) to immune microenvironment modulation (2010–2018) and now embraces mRNA-based precision immunotherapy (2019–2024). Future efforts may prioritize combinatorial nano-immunotherapies integrating metabolic regulation and AI-optimized delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.